12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

PHASE3CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

October 31, 2015

Conditions
Nasal Polyps
Interventions
DRUG

Fluticasone Propionate

Using Optinose Exhalation Delivery System

Trial Locations (16)

26554

Exemplar Research, Fairmont

27103

PMG Research of Winston Salem, Winston-Salem

33511

PAB Clinical Research, Brandon

35216

Achieve Clinical Research, Birmingham

37064

Clinical Research Solutions, Franklin

44130

HCCA Clinical Research Solutions, Middleburg Heights

53228

Allergy Asthma and Sinus Center, Greenfield

61761

Sneeze Wheeze and Itch Associates, Normal

67203

Professional Research Network of Kansas, Wichita

70115

Best Clinical Trials, New Orleans

76051

William Blake Partners, Grapevine

84020

Focus Clinical Research, Draper

84088

Advanced Clinical Research, West Jordan

84102

InterMountain Ear Nose and Throat, Salt Lake City

97401

Allergy and Asthma Research Group, Eugene

99204

Premier Clinical Research, Spokane

All Listed Sponsors
lead

Optinose US Inc.

INDUSTRY

NCT01623310 - 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device | Biotech Hunter | Biotech Hunter